---
title: "Oncology Institute - CW22 | 8-K: FY2025 Q2 Revenue: USD 119.8 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252915861.md"
datetime: "2025-08-13T20:23:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252915861.md)
  - [en](https://longbridge.com/en/news/252915861.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252915861.md)
---

# Oncology Institute - CW22 | 8-K: FY2025 Q2 Revenue: USD 119.8 M

Revenue: As of FY2025 Q2, the actual value is USD 119.8 M.

EPS: As of FY2025 Q2, the actual value is USD -0.15.

EBIT: As of FY2025 Q2, the actual value is USD -11.21 M.

### Segment Revenue

-   **Consolidated Revenue**: $119.8 million, an increase of 21.5% from $98.6 million in Q2 2024.
-   **Patient Services Revenue**: $55.9 million, up from $52.5 million.
-   **Dispensary Revenue**: $62.6 million, up from $44.4 million.
-   **Clinical Trials & Other Revenue**: $1.3 million, down from $1.7 million.

### Operational Metrics

-   **Gross Profit**: $17.5 million, an increase of 34.4%.
-   **Net Loss**: - $17.0 million, compared to - $15.5 million in Q2 2024.
-   **Adjusted EBITDA**: - $4.1 million, compared to - $8.7 million.

### Cash Flow

-   **Cash and Cash Equivalents**: $30.3 million as of June 30, 2025.
-   **Net Cash Used in Operating Activities**: - $15.2 million for the six months ended June 30, 2025, compared to - $31.5 million in 2024.
-   **Free Cash Flow**: - $14.6 million, compared to - $31.8 million in 2024.

### Unique Metrics

-   **Fee-for-Service Revenue Growth**: 10% over Q2 2024, driven by new markets.
-   **Retail Pharmacy and Dispensary Contribution**: $62.6 million in revenue and over $11 million in gross profit in Q2 2025.

### Outlook / Guidance

-   The Oncology Institute reaffirms its full-year 2025 guidance with expected revenue between $460 to $480 million and gross profit between $73 to $82 million.
-   Adjusted EBITDA is projected to be between - $8 to - $17 million, and Free Cash Flow is expected to be between - $12 to - $21 million.
-   The company anticipates reaching the higher end of its revenue guidance range for 2025, with Adjusted EBITDA expected to be approximately - $2.5 to - $3.5 million in Q3 2025.

### Related Stocks

- [TOIIW.US](https://longbridge.com/en/quote/TOIIW.US.md)
- [STLNW.US](https://longbridge.com/en/quote/STLNW.US.md)